Results 1 to 10 of about 224 (97)

Evaluation of the genetic toxicity of sofosbuvir and simeprevir with and without ribavirin in a human-derived liver cell line

open access: yesAnais da Academia Brasileira de Ciências, 2021
Direct-acting antivirals have revolutionized the treatment of chronic hepatitis C. Sofosbuvir and simeprevir are prescribed worldwide. However, there is a scarcity of information regarding their genotoxicity.
CARINA S. LIBRELOTTO   +4 more
doaj   +1 more source

Simeprevir Capsules [PDF]

open access: yesHospital Pharmacy, 2014
Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing ...
Cada, Dennis J   +2 more
openaire   +3 more sources

Physiologically‐based pharmacokinetic modeling for investigating the effect of simeprevir on concomitant drugs and an endogenous biomarker of OATP1B

open access: yesCPT: Pharmacometrics & Systems Pharmacology, 2023
The orally available anti‐hepatitis C virus (HCV) drug simeprevir exhibits nonlinear pharmacokinetics at the clinical doses due to saturation of cytochrome P450 (CYP) 3A4 metabolism and organic anion transporting peptide (OATP) 1B mediated hepatic uptake.
Shinji Nakayama   +4 more
doaj   +1 more source

Safety and Efficacy of Sofosbuvir Based Regimens in Treating Chronic ‎Hepatitis C Virus in Egyptian Patients: Real World Study: Single Center ‎Experience [PDF]

open access: yesAfro-Egyptian Journal of Infectious and Endemic Diseases, 2021
Backgroundand study aims:Hepatitis C virus (HCV) is the main leading cause of liver disease in ‎Egypt. A new era of HCV treatment has been started with the evolution ‎of direct acting antiviral agents.
Mohamed Abbasy   +6 more
doaj   +1 more source

Possibilities of using cepeginterferon alpha-2b in double (cepeginterferon alfa-2b and ribavirin) and triple (simeprevir, cepeginterferon alpha-2b, and ribavirin) antiviral therapy regimens for chronic hepatitis C. A review of clinical trials and experience of everyday clinical practice [PDF]

open access: yesТерапевтический архив, 2016
Since the incidence of chronic hepatitis C (CHC) increases steadily, the priority of national health care is to provide antiviral therapy (AVT) for the maximum number of patients infected with hepatitis C virus (HCV).
O O Znoyko   +5 more
doaj   +1 more source

REAL LIFE EGYPTIAN EXPERIENCE OF COMBINATION THERAPY (SIMEPREVIR/SOFOSBUVIR) IN EXPERIENCED NON CIRRHOTIC HCV PATIENTS [PDF]

open access: yesAl-Azhar Journal of Pharmaceutical Sciences, 2017
Background Egypt has the highest prevalent in presence of chronic HCV infection that may lead to cirrhosis, portal hypertension, hepatocellular failure and hepatocellular carcinoma.
Engy Wahsh
doaj   +1 more source

DAA - directly acting antivirals - as a new, more efficient solution of the chronic hepatitis C treatment and theirs various application.

open access: yesJournal of Education, Health and Sport, 2023
Introduction Cirrhosis is a condition in which the liver becomes fibrotic following damage to the liver and transforms the architecture of the organ into regenerative nodules.
Kamila Abram   +9 more
doaj   +1 more source

Interferon-Free Hepatitis C Treatment before and after Liver Transplantation: The Role of HCV Drug Resistance

open access: yesViruses, 2015
Hepatitis C virus (HCV) infection is one of the leading causes of end-stage liver disease and the main indication for liver transplantation (LT) in most countries.
Bruno Roche   +3 more
doaj   +1 more source

The Observed Effect of Gastric Bypass Surgery on Direct-acting Antiviral Treatment: a Case Report

open access: yesAnnals of Hepatology, 2018
Chronic hepatitis C virus (HCV) infection can be cured with treatment using direct-acting antivirals (DAAs). Although these drugs have been widely studied, information about certain special populations is missing.
Elise J. Smolders   +4 more
doaj   +1 more source

PROTEASE INHIBITOR NARLAPREVIR IN THERAPY OF HEPATITIS C VIRUS GENOTYPE 1 INFECTION IN TREATMENT-NAÏVE PATIENTS WITHOUT CIRRHOSIS: PHARMACOECONOMIC EVALUATION

open access: yesЖурнал инфектологии, 2017
The incidence of chronic hepatitis C inRussiais extremely high, that requires an increase the access to effective treatment regimens.The aim of the study is to assess the cost of HCV therapy (genotype 1) of naïve patients without cirrhosis with second ...
A. V. Rudakova   +4 more
doaj   +1 more source

Home - About - Disclaimer - Privacy